MILTON, ONTARIO--(Marketwire - March 21, 2012) - Stellar Pharmaceuticals Inc. ("Stellar") (OTCQB:SLXCF)(OTCBB:SLXCF)(PINKSHEETS:SLXCF), a Canadian public company) announced on Monday, March 19, 2012 the Company would host a conference call at 4:00 p.m. Eastern Time to discuss the details of the approval of CAMBIA®, (diclofenac potassium for oral solution) for the treatment of migraine attacks with or without aura in adults, by Health Canada as noted in the press release dated Friday, March 16, 2012. The prior access number to the taped replay of this conference call was incorrectly provided. A replay of this conference call can be heard by accessed as follows:

A taped replay of the conference call will also be available beginning approximately two hours after the call's conclusion and will remain available through 12:00 midnight Eastern Time on March 26, 2012. The replay may be accessed by dialing 800-408-3053 and entering Pass code 5515831 #. From international locations, the replay may be accessed by dialing 905-694-9451. To access the webcast, go to Stellar Web site at [ http://stellarpharma.com ]. A replay of the webcast will also be available.

About Stellar Pharmaceuticals Inc.

Stellar and its subsidiary, Tribute Pharmaceuticals, is an emerging Canadian specialty pharmaceutical company focused on the acquisition, licensing, development and management of pharmaceutical and healthcare products with its primary focus on the Canadian market.

Stellar markets Bezalip®* SR (bezafibrate), NeoVisc® (1.0% sodium hyaluronate solution), Soriatane®* (acitretin) and Uracyst® (sodium chondroitin sulfate solution 2%) in the Canadian market place. NeoVisc® and Uracyst® are sold globally through various international partnerships. Additionally, Stellar is currently in negotiations to license both NeoVisc® and Uracyst® in the US and other international markets.

For further information on Stellar Pharma, visit [ http://www.stellarpharma.com ] and for information on its subsidiary please visit [ http://www.tributepharma.com ].